Tandem Meetings – 2023 – Poster Presentation LBA14
Publications
February 16, 2023
Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias
Trem-cel
Presented by: Benjamin Tomlinson, MD – University Hospitals Seidman Cancer Center